207 articles
Glaukos marked two major 10-year milestones at RANZCO 2025: a decade since it listed on the New York Stock Exchange, and 10 years since vice-president Asia and Glaukos Australasia head Glenn Fawcett e
Read about how building awareness, recognition and engagement of women in ophthalmology is paying off.
Who's who among the 56th RANZCO Congress graduation and awards ceremony
Pharmac confirmed it will fund the anti-VEGF treatment Vabysmo (faricimab) for neovascular (wet) age-related macular degeneration and diabetic macular oedema in both public and private care.
The 2025 Specsavers Clinical Conference (SCC2025) was a glitteringly green affair, attracting nearly 1,000 optometrists from across Australia and New Zealand, from inside and outside Specsavers, to the Grand Hyatt Melbourne.
A Pharmac proposal to fund four new medicines from Roche, including the anti-VEGF treatment Vabysmo (faricimab) for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO), resulted in several hastily despatched submissions from the eyecare industry.
New Zealand glaucoma specialists have welcomed Southern Cross’ decision to partially fund the latest iteration of the minimally invasive glaucoma surgery (MIGS) device, the iStent Infinite.
Specsavers Australia and New Zealand announced the 2025 award winners of its prestigious Doug Perkins Medal and Dame Mary Perkins Award at the annual Specsavers Clinical Conference in Melbourne.
LINKS: https://nzoptics.co.nz/live-articles/save-sight-symposium-2024-ideas-and-innovations-in-eye-health/
After navigating the road tunnel to the centre of Ellerslie Racecourse and the pedestrian tunnel back to the other side on a cold, wet Sunday morning, the warm lights of the brick-built Tote On Ascot
A two-year efficacy trial of the minimally invasive glaucoma surgery (MIGS) iStent Inject W device found it significantly reduced intraocular pressure (IOP) and glaucoma medication burden in adult Jap
